| 1.4 -0.08 (-5.41%) | 09-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.75 |
1-year : | 1.96 |
| Resists | First : | 1.5 |
Second : | 1.67 |
| Pivot price | 1.47 |
|||
| Supports | First : | 1.22 |
Second : | 1.01 |
| MAs | MA(5) : | 1.45 |
MA(20) : | 1.46 |
| MA(100) : | 1.6 |
MA(250) : | 2.05  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 30 |
D(3) : | 33.3 |
| RSI | RSI(14): 36.2 |
|||
| 52-week | High : | 5.7 | Low : | 0.23 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SYBX ] has closed below the lower bollinger band by 24.4%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 53.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.44 - 1.45 | 1.45 - 1.46 |
| Low: | 1.34 - 1.35 | 1.35 - 1.36 |
| Close: | 1.38 - 1.4 | 1.4 - 1.41 |
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Sat, 10 Feb 2024
Synlogic Announces Plan to Cease Operations and Reduce Its Workforce by More Than 90% - SynBioBeta
Fri, 09 Feb 2024
Why Is Synlogic (SYBX) Stock Down 55% Today? - InvestorPlace
Thu, 08 Feb 2024
Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update - Yahoo Finance
Thu, 20 Oct 2022
Synlogic Stock: SYNB1934 Advances To Phase 3 (NASDAQ:SYBX) - Seeking Alpha
Thu, 11 Aug 2022
Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks - PR Newswire
Tue, 09 Nov 2021
Synlogic and Ginkgo Bioworks Announce Investigational Synthetic Biotic Medicine for the Treatment of Homocystinuria - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 3.61e+006 (%) |
| Held by Institutions | 15.5 (%) |
| Shares Short | 11 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.6e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 173.3 % |
| Return on Equity (ttm) | -46.1 % |
| Qtrly Rev. Growth | 3.17e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -170.7 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -4.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -49 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.95 |
| Dividend | 0 |
| Forward Dividend | 48180 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|